Posts

Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars

on

AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure (August 17, 2026)

on

Boulevard Bio launches with $65M to target IgAN and other autoimmune diseases with quarterly‑dosed BAFF/APRIL bispecific against Vera's Trutakna

on

Greg Verdine's LifeMine raises $263M for safer immunosuppressant

on

Attovia CEO Fu plans muscle in on itch market with $289M IPO to challenge Dupixent

on

Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger | ADVC001 lead-212 PSMA-targeted therapy and manufacturing expansion

on

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

on

cAMPfield Raises $180M to Bring PDE4 Inhibition to IBD

on

Portal Biotechnologies raises $9M for cell engineering tech that’s attracted Merck & Co., AbbVie

on

Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact

on

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

on

Parabilis’ record $670M IPO to fund cancer drug and platform expansion

on

Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

on

Pfizer's next-gen pneumonia shot beats Prevnar 20 in infant trial

on

Odyssey Therapeutics Secures $279M IPO Amid Biotech Funding Challenges

on

No Recent News Found on Samsung Biologics' $102M Strike Impact

on

Hemab and Seaport Post Gains on NASDAQ After Raising $550M Across Their Debuts

on

Avalyn Pharma Aims for $182M IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs

on

Sage Alumni Launch Tortugas with $106M to Advance CNS Pipeline

on

Kailera CEO Confident Before Record-Breaking $625M Obesity Biotech IPO

on